Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Withdrawn plasma study leaves COVID-19 pneumonia treatment question unanswered

NCT ID NCT04333251

Disease control Sponsor: Baylor Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to test whether giving antibody-rich plasma from recovered COVID-19 patients could help hospitalized adults with pneumonia caused by the virus. The trial was withdrawn before any participants were enrolled, so no data was collected. The approach was based on the idea that donated antibodies might boost the immune response and reduce the need for oxygen or breathing support.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
convalescent plasma (antibody-rich blood plasma from recovered COVID-19 patients)
What this could lead to
If it had worked, this could have pointed toward a treatment for severe COVID-19 pneumonia using donated plasma from recovered patients.
What could go wrong
This trial was withdrawn before enrolling anyone, so no results are available. Convalescent plasma carries risks like allergic reactions or lung injury, and its effectiveness was uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Started

Apr 2020

Finished

Sep 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Donor: * 18 years or older * must have been hospitalized w/COVID-19 respiratory symptoms and confirmation via COVID-19 SARS-CoV-2 RT-PCR testing but are now PCR negative by 2 nasopharyngeal testing * females of child-bearing potential must have a negative serum pregnancy test * subject and/or LAR willing to provide informed consent * patient agrees to storage of specimens for future testing Inclusion Criteria Recipient: * 18 years or older * must have been hospitalized w/COVID-19 respiratory symptoms within 3 to 7 days from the beginning of illness * subject and/or LAR willing to provide informed consent * patient agrees to storage of specimens for future testing Exclusion Criteria: * 18 years or older * receipt of pooled immunoglobulin in past 30 days * contraindication to transfusion or history of prior reactions to transfusion blood products * females who are identified as donors must not be pregnant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 interstitial pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

interstitial lung disease non-specific interstitial pneumonia viral pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumonia, interstitial

More trials for these conditions

Other studies related to the condition(s) this trial covers.